| Literature DB >> 34898420 |
Wenhui Huang1, Gin Tsen Chai1,2, Bernard Yu-Hor Thong1, Mark Chan1, Brenda Ang1, Angela Chow1,2.
Abstract
Introduction. During the early days of coronavirus disease 2019 (COVID-19) in Singapore, Tan Tock Seng Hospital implemented an enhanced pneumonia surveillance (EPS) programme enrolling all patients who were admitted from the Emergency Department (ED) with a diagnosis of pneumonia but not meeting the prevalent COVID-19 suspect case definition.Hypothesis/Gap Statement. There is a paucity of data supporting the implementation of such a programme.Aims. To compare and contrast our hospital-resource utilization of an EPS programme for COVID-19 infection detection with a suitable comparison group.Methodology. We enrolled all patients admitted under the EPS programme from TTSH's ED from 7 February 2020 (date of EPS implementation) to 20 March 2020 (date of study ethics application) inclusive. We designated a comparison cohort over a similar duration the preceding year. Relevant demographic and clinical data were extracted from the electronic medical records.Results. There was a 3.2 times higher incidence of patients with an admitting diagnosis of pneumonia from the ED in the EPS cohort compared to the comparison cohort (P<0.001). However, there was no significant difference in the median length of stay of 7 days (P=0.160). Within the EPS cohort, stroke and fluid overload occur more frequently as alternative primary diagnoses.Conclusions. Our study successfully evaluated our hospital-resource utilization demanded by our EPS programme in relation to an appropriate comparison group. This helps to inform strategic use of hospital resources to meet the needs of both COVID-19 related services and essential 'peace-time' healthcare services concurrently.Entities:
Keywords: COVID-19; hospital-resource utilization; pneumonia surveillance
Mesh:
Year: 2021 PMID: 34898420 PMCID: PMC8744277 DOI: 10.1099/jmm.0.001452
Source DB: PubMed Journal: J Med Microbiol ISSN: 0022-2615 Impact factor: 2.472
Relevant clinical variables for comparison cohort (2019) and EPS cohort (2020)
|
Comparison (2019)
|
EPS (2020)
|
| |
|---|---|---|---|
|
| |||
|
Total number of admissions |
6985 |
6949 | |
|
Admissions with pneumonia as admitting diagnosis |
403 |
1295 | |
|
Incidence of pneumonia (per 10 000 admissions) |
577 |
1864 |
<0.001 |
|
| |||
|
1. Age (years) |
74 (59–83) |
77 (67–85) |
0.008 |
|
2. Male |
190 (47.1 %) |
708 (54.7 %) |
0.008 |
|
| |||
|
3. LOS (days) |
7 (4–13) |
7 (4–11) |
0.160 |
|
4. Death at the end of hospitalization |
39 (9.7 %) |
93 (7.2 %) |
0.102 |
|
| |||
|
5. CXR |
|
| |
|
Reported as normal |
9 (2.2 %) |
102 (8.1 %) |
<0.001 |
|
6. Chest CT imaging |
|
|
0.089 |
|
| |||
|
7. Influenza A and B PCR |
|
| |
|
Positive (either) |
27 (9.0 %) |
7 (0.8 %) |
<0.001 |
|
8. Respiratory virus multiplex PCR |
|
| |
|
Positive (any organism) |
4 (23.5 %) |
10 (17.9 %) |
0.603 |
|
9. Urinary Legionella antigen |
|
| |
|
Positive |
0 |
0 |
|
|
10. Urinary Streptoccocal antigen |
|
| |
|
Positive |
5 (2.5 %) |
12 (2.3 %) |
0.923 |
|
11. Sputum AFB smear and culture |
|
| |
|
Smear positive |
10 (7.1 %) |
6 (2.7 %) |
0.045 |
|
Culture positive for |
3 (5.7 %) |
0 |
|
|
12. Sputum |
|
| |
|
Smear positive |
0 |
0 |
|
|
Total performed (items 7–12) |
866 |
2193 | |
|
| |||
|
12. WBC (x 109 l−1) |
|
| |
|
Median |
9.2 (7.0–12.0) |
8.6 (6.5–11.9) |
0.041 |
|
Range | |||
|
<4 |
8 (2.0 %) |
55 (4.3 %) |
0.036 |
|
4–10 |
227 (56.6 %) |
746 (57.6 %) | |
|
>10 |
166 (41.4 %) |
489 (37.9 %) |
0.210 |
|
13. C-reactive protein (mg l−1) |
|
| |
|
Median |
44.8 (14.3–93.4) |
24.6 (5.8–87.6) |
<0.001 |
|
14. Procalcitonin (µg l−1) |
|
|
0.111 |
|
Median |
0.20 (0.08–0.49) |
0.15 (0.08–0.46) |
0.070 |
Data are presented as median (interquartile range) or numbers (%).
CT, computed tomography; CXR, chest x-ray.
Inpatient antimicrobial use for comparison cohort (2019) and EPS cohort (2020)
|
Comparison (2019)
|
EPS (2020)
|
| |
|---|---|---|---|
|
|
|
| |
|
Amoxicillin and Clavulanate |
334 (82.9 %) |
892 (68.9 %) |
<0.001 |
|
Clarithromycin |
226 (56.1 %) |
405 (31.3 %) |
<0.001 |
|
Azithromycin |
49 (12.2 %) |
43 (3.3 %) |
<0.001 |
|
Ceftazidime |
48 (11.9 %) |
55 (4.2 %) |
<0.001 |
|
Crystalline Penicillin G |
46 (11.4 %) |
43 (3.3 %) |
<0.001 |
|
Doxycycline |
45 (11.2 %) |
76 (5.9 %) |
<0.001 |
|
Levofloxacin |
39 (9.7 %) |
76 (5.9 %) |
0.008 |
|
|
|
| |
|
Piperacillin and tazobactam |
126 (31.3 %) |
352 (27.2 %) |
0.111 |
|
Vancomycin |
108 (26.8 %) |
277 (21.4 %) |
0.024 |
|
Meropenem |
26 (6.5 %) |
72 (5.6 %) |
0.503 |
|
|
|
| |
|
Oseltamivir |
65 (16.1 %) |
107 (8.3 %) |
<0.001 |
|
|
|
| |
|
Trimethoprim-sulfamethoxazole (Co-trimoxazole) |
7 (1.7 %) |
20 (1.5 %) |
0.787 |
|
Pentamidine Isetionate (nebulized) |
1 (0.2 %) |
4 (0.3 %) |
0.845 |
|
Clindamycin |
4 (1.0 %) |
23 (1.8 %) |
0.272 |
|
Primaquine |
1 (0.2 %) |
2 (0.2 %) |
0.696 |
|
|
|
| |
|
Rifampicin |
8 (2.0 %) |
16 (1.2 %) |
0.266 |
|
Isoniazid |
8 (2.0 %) |
16 (1.2 %) |
0.266 |
|
Ethambutol |
7 (1.7 %) |
16 (1.2 %) |
0.477 |
|
Pyrazinamide |
5 (1.2 %) |
5 (0.4 %) |
0.050 |
Selected, non-pneumonia discharge diagnoses for comparison cohort (2019) and EPS cohort (2020)
|
Discharge diagnosis |
Comparison (2019)
|
EPS (2020)
|
|
|---|---|---|---|
|
|
14 (3.5 %) |
62 (4.8 %) |
0.265 |
|
Acute myocardial infarction |
4 |
11 | |
|
Arrhythmia |
1 |
7 | |
|
Congestive cardiac failure |
9 |
37 | |
|
Others* |
0 |
7 | |
|
|
2 (0.5 %) |
2 (0.2) |
0.240 |
|
Pulmonary embolism |
2 |
2 | |
|
|
0 (0 %) |
19 (1.5 %) |
0.01 |
|
Haemorrhagic or ischaemic stroke |
0 |
16 | |
|
Transient ischaemic attack |
0 |
2 | |
|
Obstructive hydrocephalus |
0 |
1 | |
|
|
1 (0.2 %) |
43 (3.3 %) |
<0.001 |
*Others include angina, cardiac arrest, cardiomyopathy and primary pulmonary hypertension.